
## Mircea Tesileanu

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8876524/publications.pdf Version: 2024-02-01

version. 2024-02-01



#	Article	IF	CITATIONS
1	<i>MGMT</i> promoter methylation determined by the MGMT-STP27 algorithm is not predictive for outcome to temozolomide in IDH-mutant anaplastic astrocytomas. Neuro-Oncology, 2022, 24, 665-667.	1.2	5
2	Prognostic Significance of DNA Methylation Profiles at MRI Enhancing Tumor Recurrence: a Report from the EORTC 26091 TAVAREC Trial. Clinical Cancer Research, 2022, 28, 2440-2448.	7.0	3
3	Temozolomide and Radiotherapy versus Radiotherapy Alone in Patients with Glioblastoma, <i>IDH</i> -wildtype: <i>Post Hoc</i> Analysis of the EORTC Randomized Phase III CATNON Trial. Clinical Cancer Research, 2022, 28, 2527-2535.	7.0	27
4	Prognostic significance of genome-wide DNA methylation profiles within the randomized, phase 3, EORTC CATNON trial on non-1p/19q deleted anaplastic glioma. Neuro-Oncology, 2021, 23, 1547-1559.	1.2	34
5	Survival of diffuse astrocytic glioma, IDH1/2 wildtype, with molecular features of glioblastoma, WHO grade IV: a confirmation of the cIMPACT-NOW criteria. Neuro-Oncology, 2020, 22, 515-523.	1.2	140